Alnylam Pharmaceuticals has seen its Fair Value Estimate rise from $467.94 to $480.17, reflecting a modestly stronger outlook supported by recent analyst enthusiasm. This updated assessment comes ...
TaskUs delivered a positive third quarter as the market reacted favorably to strong revenue growth and improved profitability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback